Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · Lancet · 2026-09-17

In 476 virologically suppressed adolescents with HIV in sub-Saharan Africa, 8-weekly injectable cabotegravir-rilpivirine beat daily oral TLD: confirmed viral rebound by week 96 was 0.9% vs 6.4% (difference -5.5%), non-inferior and superior.

RCTn = 476
Bwakura-Dangarembizi et al. Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
Infectious diseases · Lancet · 2026-09-11

In 1784 Ugandan children aged 9–23 months, one-fifth and one-half fractional doses of 17DD yellow fever vaccine were non-inferior to the full dose for seroconversion at 4 weeks (5-point margin); no difference for one-fifth and −0·17 for one-half vs full dose (per protocol).

RCTn = 1,784
Doshi et al. Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.